This year, the members of the association met in Bologna, Italy, for their annual general assembly. At this meeting, Klaus-Peter Behr, Chairman of EMAV, pointed out that during the reporting period, EMAV was confronted with a number of new challenges regarding the manufacturing and future availability of autogenous vaccines, which EMAV was able to successfully overcome thanks to consistently focused work, a proven and dedicated team and the use of an established network.